Introduction {#Sec1}
============

In a previous paper we introduced the Turkish Injection Technique Questionnaire (ITQ) survey patient population and injecting practice \[[@CR1]\]. Based on the results, Turkish best practice recommendations were drafted and endorsed by Turkish health care professionals (HCP). We propose to continue this exposé, using the same approach, for injecting complications.

Methods {#Sec2}
=======

Our previous paper \[[@CR1]\] described the methods, materials, centers, and patients who participated in the study.

Ethical Considerations {#Sec3}
----------------------

No participant-identifying information was made available to the sponsor and participants were informed that their care would not be affected in any way by their participation. They were not put at risk in any way by the study and were not paid to participate. Ethics committee approval was therefore not generally required but was obtained whenever specifically requested by a center and/or by local regulations. All 56 participating centers from 29 cities in Turkey (as in the rest of world, ROW) did so willingly and without financial incentive.

Results {#Sec4}
=======

Lipohypertrophy {#Sec5}
---------------

Patients were asked: Do you have any swelling or lumps under the skin at your usual injection sites that have been there for some time (weeks, months, or years)? Table [1](#Tab1){ref-type="table"} gives the results for both the patients' answers and the nurses' examination of all patient injection sites. Turkish results are given beside ROW. The latter constitute the values from the 41 other ITQ participating countries combined (excluding Turkey). Percentages of lipohypertrophy (LH) in Turkey were lower than in ROW (27.4% vs 31.5%, respectively).Table 1Lipohypertrophy in Turkey vs ROW% Turkey\
*N* = 1364% ROW\
*N* = 7657Presence of lypohypertrophy as per patient report31.229.0Presence of lypohypertrophy as per nurse examination27.431.5Rest of world (ROW) constitutes the values from the 41 other ITQ participating countries combined (excluding Turkey)

Nurses examined each of the patient's injection sites both visually and by palpation and reported any LH (Table [2](#Tab2){ref-type="table"}). When nurses found LH they were asked to measure the lesions along their longest dimension in millimeters. Table [3](#Tab3){ref-type="table"} shows that LH size in Turkish patients was on average slightly lower in the abdomen and thigh and almost the same in the arm. Whenever nurses found LH they asked the patient if they were still injecting into it and 58.8% of Turkish patients said yes. They were then asked how often they did so (Table [4](#Tab4){ref-type="table"}). Patients who injected into LH were also asked why they did so (Table [5](#Tab5){ref-type="table"}). More than half of Turkish patients answered "Don't know" to that question.Table 2Nurse-confirmed lipohypertrophy in Turkish and ROW patientsSiteExam type% Turkey\
*N* = 1259% ROW\
*N* = 6306AbdomenVisual12.918.2Palpation14.222.6ThighVisual6.910.6Palpation8.112.1ButtocksVisual0.82.3Palpation1.43.2ArmVisual11.810.9Palpation14.413.0 Table 3Size of nurse-measured lipohypertrophy (LH) in Turkish (*N* = 384) and ROW (*N* = 1816) patientsSize^a^Turkey (mean mm)ROW (mean mm)*N* Turkey*N* ROWAbdominal LH36.545.51541166Thigh LH32.343.983404Arm LH35.535.9147246^a^Size was measured as the longest dimension (usually the diameter) of the largest LH lesion present in the stated anatomic site of injection Table 4Frequency of injection into LH in Turkish and ROW patientsFrequency% Turkey\
*N* = 276% ROW\
*N* = 1688Every injection14.517.1Frequently (daily)49.337.9Occasionally (weekly)31.530.2Seldom (monthly)4.714.9 Table 5Reasons patients report injecting into LH in Turkish and ROW patientsReason% Turkey\
*N* = 345% ROW\
*N* = 1602It's convenient18.011.6It's less painful23.817.4Just a habit31.931.5Don't know26.428.3

The worldwide ITQ data \[[@CR2], [@CR3]\] showed a strong association between the presence of LH and the total daily dose (TDD) of insulin. Over 10 international units (IU) of insulin on average was consumed in persons with lipohypertrophy (LH+) vs persons without lipohypertrophy (LH−). In type 2 diabetes (T2DM) patients, this average TDD difference is 13.5 IU. In type 1 diabetes (T1DM) patients, the average TDD difference is 5.4 IU. The presence of LH is associated with higher glycated hemoglobin (HbA1c) values, an average difference of 0.55. In Turkey the LH+ population had an average TDD of 59.2 IU while the LH− group averaged 52.2 IU, a 7.0 IU spread (*p* \< 0.01). In Turkish T1DM patients the difference in TDD between LH+ and LH− patients was only 0.8 IU (higher in LH+) but this did not achieve statistical significance (*p* = 0.766). However in T2DM the difference was striking; TDD was 13.2 IU higher in LH+ patients than in LH− (*p* \< 0.001). There was also a highly significant difference in HbA1c between LH+ and LH− subjects, 9.61 vs 8.85, respectively (*p* \< 0.001).

LH is associated with not rotating injection sites properly, injecting into small areas rather than broadly spreading out injections, using insulin for many years, and reusing needles. These associations are not necessarily causative of LH, but they emerge in so many studies that their role in LH formation is now widely accepted.

Our definitions of "hypoglycemia", "frequent unexplained hypoglycemia", and "glycemic variability" have been reported in previous studies \[[@CR3], [@CR4]\]. In the ITQ nurses reviewed the blood glucose meter results and medical records of each subject to determine who qualified for the three aforementioned complications. About a quarter of Turkish injectors had frequent unexplained hypoglycemia and about 40% had glucose variability (Table [6](#Tab6){ref-type="table"}). In Turkish patients with these complications, LH was more common. Table [7](#Tab7){ref-type="table"} gives results for lipoatrophy.Table 6Frequency of unexplained hypoglycemia and glycemic variability in Turkish and ROW patients% Turkey% ROW*N* Turkey*N* ROWFrequent unexplained hypoglycemia^a^ Yes25.218.33411239 No74.881.710115547Glycemic variability^b^ Yes38.034.85132359 No62.065.28364415^a^Hypoglycemia is defined as the occurrence of  at least one symptom of low sugar (e.g., palpitations, tiredness, sweating, strong hunger, dizziness, tremor) and a confirmed blood glucose meter reading ≤ 60 mg/dL (3.3 mM/L). Frequent unexplained hypoglycemia is defined as hypoglycemia occurring one or more times weekly in the absence of a definable precipitating event such as a change in medication, diet, or activity^b^Glycemic variability is the presence of blood glucose oscillations from less than 60 mg/dL (3.3 mM/L) to more than 250 mg/dL (13.9 mM/L) at least three times a week in an unpredictable and unexplained fashion and evidence of such a pattern for at least the previous 6 months Table 7Nurse-reported lipoatrophy and redness in Turkish and ROW patientsSiteFinding% Turkey\
*N* = 1259% ROW\
*N* = 7565AbdomenLipoatrophy0.60.6Redness4.83.3ThighLipoatrophy0.40.5Redness5.02.8ButtocksLipoatrophy0.00.2Redness0.20.4ArmLipoatrophy0.50.4Redness7.63.6

Rotation of Injection Sites {#Sec6}
---------------------------

Patients who give their injections a minimum of 1 cm from previous ones are said to rotate correctly. Such patients, according to worldwide ITQ results, have less glycemic variability, fewer hypo- and hyperglycemic episodes, and less LH \[[@CR3]\]. They also have lower HbA1c values and use less insulin (lower TDD) than patients who do not rotate correctly, again related to the presence of LH. We found that 74.4% of Turkish injectors rotated their sites correctly (Table [8](#Tab8){ref-type="table"}).Table 8Frequency of correct rotation: Turkey vs ROWTurkey\
*N* = 1263ROW\
*N* = 6730Practice correct rotation^a^74.469.9^a^Correct rotation is defined as always injecting at least 1 cm from previous injection(s)

Bleeding, Bruising, Pain, and Leakage {#Sec7}
-------------------------------------

Bruising or bleeding at injection sites is commonly reported, a finding that is worrying to patients but is seldom of clinical importance. In our survey 52.0% of Turkish injectors reported these findings; however, only 1.9% said it occurred "always", 22.7% reported it happened "often" (several times a week), but the majority, 53.2%, said it occurred only "sometimes" (several times a month). Nearly a quarter (22.2%) said that they saw it "almost never" (several times a year).

Approximately half of Turkish patients have pain on injection, but as with bruising, this occurred rarely. The same held for insulin leaking out of the skin at injection sites. One-third reported leakage, but, of those who did, nearly three quarters said it was rare.

Table [9](#Tab9){ref-type="table"} shows who gave patients their injection training. This is usually done by diabetes nurses in Turkey. This may be because general nurses are less involved in diabetes management in Turkey than in ROW.Table 9Professional who gave patient injection trainingInjection instructor% Turkey\
*N* = 1359% ROW\
*N* = 8081General nurse16.124.0Diabetes nurse70.142.8Diabetes educator6.013.3Doctor (general practitioner)0.95.8Doctor (diabetes specialist)4.210.9Pharmacist1.82.1Representative of the pen/needle manufacturer1.01.1

Table [10](#Tab10){ref-type="table"} shows how frequently injection sites are checked in Turkey by HCP and the results are very similar to ROW. Nevertheless the goal of checking injection sites at least once a year is not being met for the majority of patients. Patients were asked when they last received instruction or advice on injections. Table [11](#Tab11){ref-type="table"} shows that Turkey is performing considerably better than ROW in giving advice within the last year.Table 10Frequency with which injection sites are checkedFrequency% Turkey\
*N* = 1204% ROW\
*N* = 11,301Routinely every visit27.328.4Once a year11.212.8Only if I complain of a problem at a site25.519.6I can't remember my sites ever being checked36.039.2 Table 11Last time patient given instructions or advice on injectionsFrequency% Turkey\
*N* = 1326% ROW\
*N* = 8262Within the past 6 months49.435.4Within the past 6--12 months27.416.0Sometime in the last 1--5 years13.622.8Sometime in the last 5--10 years5.114.8Never4.510.9

Turkish patients were asked to report which injection topics they could not remember ever being trained on. Table [12](#Tab12){ref-type="table"} shows that for most topics, a similar percentage of Turkish patients could not remember being trained as in ROW.Table 12Topics patients cannot remember ever being trained onTopic% Turkey\
*N* = 1265% ROW\
*N* = 8790Injection sites (e.g., thigh, arm, buttock, abdomen)12.811.6Skin thickness and appropriate depth of injection21.727.2Length of needle24.425.6How to do a skin lift or "pinch up" the skin20.718.2How long to hold a skin lift or "pinch up"23.925.7Angle of needle entry11.216.1How long to keep the needle in the skin after injection13.116.4Rotating within an injection site22.318.4Prevention of air bubbles (syringe) or proper priming of pen needle23.119.7Mixing insulin in a syringe (for syringe users)25.230.3Re-suspension of cloudy insulin24.025.0Single use of pen needle/syringe13.119.0Safe disposal of sharps (pen needles, syringes)37.528.2

Table [13](#Tab13){ref-type="table"} shows the identity of the HCP who filled out the ITQ. Turkish diabetes nurses had the highest percentage, higher than in ROW. Most Turkish HCP (89.9% or 133 of 148) knew about the new injection recommendations \[[@CR5]\] and almost all had changed their practice as a consequence.Table 13Professional who filled out the ITQProfessional% Turkey\
*N* = 150% ROW\
*N* = 1113General nurse9.318.1Diabetes nurse88.751.7Diabetes educator2.025.6Doctor (general practitioner)0.01.2Doctor (specialist)0.03.4

Discussion {#Sec8}
==========

Injecting insulin is not without its risks \[[@CR6]\]. These include intramuscular (IM) or intradermal (ID) injections, which often distort the pharmacokinetics (PK) and pharmacodynamics (PD) of insulin and may lead to adverse effects on glucose control; injection pain, bruising, bleeding; leakage of insulin from injection sites or the device itself; and LH. The last of these is probably the most common serious complication of incorrect injection technique, even though others often get more attention than LH \[[@CR7]\].

LH has been the subject of considerable recent research. These lesions had largely been ignored or unknown prior to recent studies. It takes considerable skill and training before HCP can reliably diagnose LH. For example HCP should use specific palpation techniques and should learn the value of performing a skin lift or pinch for diagnosis of LH. They should understand how to compare inelastic skin to soft, elastic and easily liftable skin \[[@CR8]\]. They should also be trained in the use of gels to achieve better lubrication and enhanced sensitivity of the fingers for detecting LH.

The better the HCP is trained at using these techniques the higher the prevalence of LH detected. The fact that LH is frequent (present in up to 2/3 s of injectors in one recent study \[[@CR9]\]), that patients and HCP are in many cases unaware of its existence, and that patients often continue to inject into it---sometimes consciously, most often unwittingly---have come as an unwelcome surprise to the diabetes community.

In an earlier study in Turkey, Vardar and Kizilci \[[@CR10]\] found LH in 48.8% of 215 insulin-injecting patients. By logistic regression analysis, they were able to identify three independent risk factors for LH: long-term insulin use (*p* = 0.001); failure to carefully rotate injection sites (*p* = 0.004); and the reuse of insulin needles (*p* = 0.004). Two other studies \[[@CR9], [@CR11]\] support these as the main risk factors for LH.

Our survey found that nearly one-third of Turkish insulin users described lesions consistent with LH at their injection sites and that an almost equal percentage were found to have LH by the examining nurse (using visual inspection and palpation). These values are consistent with those found in ROW but are lower than those in many studies in which nurses had been carefully trained to look for LH \[[@CR9], [@CR12]--[@CR15]\]. The ITQ was performed in Turkish centers with dedicated diabetes nurses. However in Turkey there are only about 500 such nurses for the 7 million diabetic patients. Hence not all insulin injectors have the opportunity to receive training from them. This means that the true prevalence of LH could be considerably higher than what we found. In fact the Turkish values for LH found in the 2009 ITQ \[[@CR16]\] are even lower than those found in 2015 (Table [14](#Tab14){ref-type="table"}), possibly because nurses in earlier years were even less trained to look for LH than they are now.Table 14Comparison of previous Turkish ones (2009) with latest Turkish ITQ results (2015)Parameter20092015Number of participants5971376Number of participating centers1856Age of participants (mean in years)48.145.0Duration of therapy (mean in years)6.96.9BMI of participants (kg/m^2^, mean)28.328.5HbA1c (%, mean)8.29.1Participants using insulin pen98.3%98.1%Participants using 8 mm needle83.5%34.7%Participants using needle \> 8 mm5.3%0.9%Participants using needle \< 8 mm11.2%64.4%Participants injecting into abdomen^a^88.9%86.5%Participants injecting into thigh^a^75.5%80.1%Participants injecting into buttocks^a^10.8%20.5%Participants injecting into arm^a^66.7%84.2%Participants injecting using pinch up87.7%52.3%Rotation of injection sites89.7%90.2%Prevalence of occasional bleeding or bruising81.4%60.2%Prevalence of patient-reported LH31.1%31.2%Prevalence of nurse-discovered LH21.8%27.4%Participants who reuse pen needles44.2%24.2%Injections sites checked on every office visit18.8%27.3%Needles disposed into rubbish directly80.8%70.0%Disposal into rubbish without recapping8.6%5.8%^a^Percentages add to over 100 because patients use multiple sites

Hence we may be fairly sure that a third of current Turkish insulin-using patients have LH at one or another of their injection sites (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}) and over half of these continue to inject into it at least daily (Table [4](#Tab4){ref-type="table"}). Reasons for doing this are similar in Turkey as in ROW: convenience, habit, and pain-avoidance (Table [5](#Tab5){ref-type="table"}). Turkish nurses who examined injection sites found more LH by palpation than they did visually (Table [2](#Tab2){ref-type="table"}), a pattern that holds also in ROW. This points to the importance of examining sites carefully using both the eyes and hands. Nurses should lubricate their hands with gel before the exam and use an undulating, circular motion, similar to the one used to examine the breast. Table [3](#Tab3){ref-type="table"} shows that LH lesions in Turkey average about 35 mm (3.5 cm), a dimension easy enough to detect, once one begins to look for them.

Almost all studies of patients injecting into LH show insulin absorption to be unpredictable and/or delayed, often leading to poor glucose control \[[@CR17]--[@CR21]\]. In the best one of these studies, glucose clamps were used in patients with LH \[[@CR22]\] to assess PK and PD when insulin was injected into LH compared to normal tissue. Results showed that PK is substantially blunted in LH injections and PD is much more variable compared to injections into normal tissue. A mixed meal study in the same patient population confirmed the slower PK and decreased PD of insulin when LH injections are compared with those into normal tissue, with much greater glucose excursions post-meal in the former case.

More than a quarter of Turkish patients have frequent unexplained hypoglycemia and nearly 2 out of 5 have glycemic variability (Table [6](#Tab6){ref-type="table"}), both of which have been linked to the presence of LH and the habit of injecting into it \[[@CR3]\]. Therefore, Turkish patients with LH should be instructed to stop injecting into LH and move to healthy sites without LH. Once patients begin injecting in these new sites they will need to reduce their insulin dose, likely by up to 20%. HCP should instruct patients to reduce doses immediately, starting with the first injection into non-LH tissue. Insulin injected into the new sites has a normal PK and PD and if patients continue with their usual doses this will almost always result in hypoglycemia.

Injections should be rotated so that new injections are always given in a different site (at least 1 cm) from previous ones. Patients should also refrain from reusing needles, since used needles may cause more tissue trauma and increase the risk for LH. Turkish patients without LH should be instructed to carefully follow the rotation and reuse advice above in order to avoid LH in the future. Several studies have shown that the surest way to keep tissue healthy is to consistently rotate injection sites as described above \[[@CR23]--[@CR25]\]. We found that Turkish patients who did rotate sites were largely following this 1-cm rule already (Table [8](#Tab8){ref-type="table"}).

Education seems to work when it comes to LH. In a multicenter interventional study in the UK \[[@CR26]\] an educational approach focused on the above recommendations (rotating sites, using 4-mm needles, and no reuse) resulted in significantly lower clinically detectable LH levels after 6 months. LH either disappeared completely or decreased by approximately half its original size. The average HbA1c decreased by more than 4 mmol/L (approximately 0.5%) and there were significantly lower levels of unexplained hypoglycemia and glucose variability. The mean TDD decreased by 5.6 IU by study end.

In a prospective, controlled, multicenter study in France, in which all patients had LH \[[@CR27]\], an intervention similar to that in the UK study led to a significant decrease of TDD (5 IU vs baseline, *p* = 0.035), decreases in HbA1c (mean fall of 0.5%), and significant improvement in injection technique habits after 6 months. In a recently published study in Russia \[[@CR28]\] patients who received interventions similar to the above had HbA1c falls of approximately 1% in a similar time period.

In the Turkish study, as with ROW, we did not find that key injection parameters (e.g., correct rotation, avoidance of LH, appropriate needle length, correct use of skin folds, single use of needles, safe sharps disposal) were better or worse as a function of duration of insulin therapy. Patients who have been injecting insulin for years often have engrained errors in technique and need the same training and education as newer-to-insulin patients.

In Turkey the diabetes nurse has by far the largest role in teaching patients how to inject. Nearly 40% of Turkish injectors get their sites checked at least annually, and a larger proportion than ROW had received recent (within the last 12 months) instruction on how to inject properly. Unfortunately the optimal timing for inspection of injection sites for LH and other complications has not yet been established by clinical studies. Similarly, the optimal timing for giving injection training is still unstudied. Nevertheless the new insulin delivery recommendations elaborate strategies for both based on experience and consensus opinion \[[@CR5]\]. More than 60% of Turkish patients reported that they can not remember their sites ever being checked or only get them checked if they complained. This clearly indicates that we still need to focus on appropriate injection techniques in the country.

Table [14](#Tab14){ref-type="table"} compares the ITQ results from 2009 with those of 2015 for certain key parameters. The two study populations were not the same and the questionnaires were slightly different, but there was sufficient overlap to justify our comparison. It is clear that there has been a dramatic "shift to short" in terms of needle length. With this shift, fewer patients are pinching up the skin; in fact with the shortest (4 mm) needle this is no longer needed, except in very select populations. Bleeding and bruising are also down. Several other encouraging signs are seen: pen needle reuse is less frequent, more patients are having their injection sites checked at each office visit, and disposal of used sharps is somewhat better. However HbA1c is higher in our most recent study, for unknown reasons. For most other parameters, including body mass index (BMI), injection sites used, and LH, the values are essentially unchanged.

Limitations {#Sec9}
-----------

Like all broad surveys that aim to be representative, the ITQ cast a wide net for both patients and HCP. Our patient population included a spectrum of patients from those who had had best-in-class training for injection technique to those who reported getting no injection training at all. Most, however, fell somewhere in between. Consequently the patient injection practices we report on here span from optimal to the clearly substandard and even dangerous. Similarly, the injection technique expertise of HCP varied widely as well. It was, for example, impossible to train all HCP to the same level of expertise in the diagnosis of LH. Recent studies have shown that flat or non-palpable LH requires a much higher level of expertise to diagnose than visible or easily palpable LH. Flat or non-visible LH can be identified by pinching the skin where the presence of LH is suspected and comparing the thickness of the skin fold with nearby normal areas \[[@CR29], [@CR30]\]. It is probable that we included HCP who might be proficient at diagnosing easily detected lesions, but not the more subtle ones. This might account for the relatively low percentages of LH detected compared to findings in other published studies where HCP were carefully trained in LH detection. However, we believe this broad approach, though limiting our study in some respects, best reflects the real world of injection practice in Turkey and ROW.

Conclusions {#Sec10}
===========

In summary, Turkish patients and professionals have clearly made progress in injection technique, but there are still considerable challenges ahead which the new injection techniques and treatment guideline for health care professionals will help address. This study provides a basis for improving the injection site examination in general clinical practice and also creating protocols for detecting and preventing LH in Turkey. The authors plan to conduct another ITQ approximately 1 year after these guidelines are published in order to assess their impact on Turkish injection practice.

Appendix {#Sec90}
========

Table 15Health care professionals who participated in this studyCityCenterName of diabetes nursePatientsAdanaCukurova Universitesi Tip Fakultesi Balcali HastanesiAYFER BAHTİYAR32GÜLCAN DELİDAĞ (Pediatric Diabetes Nurse)AfyonAfyon Kocatepe Universitesi HastanesiNUR ŞERİF KARADEMİR31SONGÜL UÇARAmasyaSabuncuoglu Serefeddin Egitim ve Arastirma HastanesiÇAĞLA DEMİR25AnkaraAnkara Ataturk Egitim Ve Arastirma HastanesiBİRGÜL GENÇ25AnkaraSBU Ankara Dr. Sami Ulus Kadın Dogum Cocuk Sagligiı ve Hastaliklari Egitim Ve Arastirma HastanesiNURDAN YILDIRIM (Pediatric Diabetes Nurse)37AnkaraHacettepe Universitesi HastanesiAYŞE İLHAN32AnkaraHacettepe Universitesi Ihsan Dogramaci Cocuk HastanesiSERPİL ÇAKMAK (Pediatric Diabetes Nurse)21AnkaraOzel Bayindir HastanesiSEVİLAY SUNGUR YURDAKUL35HANİFE AKMANNERİMAN TARHANAnkaraDiskapi Yildirim Beyazit Egitim Ve Arastirma HastanesiFATMA GÖROĞLU25AntalyaAkdeniz Universitesi HastanesiŞEFİKA DALKIRAN25DenizliDenizli Devlet HastanesiHAFİZE KANYILMAZ29GÖKÇE GÖKÇEAntalyaSaglik Bilimleri Universitesi Antalya Egitim ve Arastirma HastanesiAYFER UMAY6AYSUN ÜNALSEHER DEMİRBalikesirAyvalik Devlet HastanesiSEVGİ DUMAN18BalikesirDevlet HastanesiRABİA CEYLAN SALI25BoluAbant Izzet Baysal Universitesi Tip Fakultesi HastanesiSATI CAN25BursaSBU Bursa Yuksek Ihtisas Egitim Arastirma HastanesiSİBEL YAVAŞ19BursaUludag Universitesi Saglik Uygulama Ve Arastima HastanesiGÜLSEV DİRİK33BursaBursa Yenisehir Devlet HastanesiİLDA EROL25ÇanakkaleCanakkale Devlet HastanesiHACER KARABULUT16DiyarbakirDiyarbakır Cocuk Hastaliklari HastanesiMÜLKİYE AYDIN25DüzceAtaturk Devlet HastanesiİLKAY BAYRAM31EdirneTrakya Universitesi Saglik Araştırma ve Uygulama MerkeziÖZLEM COŞAR ÜNAL31BURCU KESKİN (Pediatric Diabetes Nurse)ErzurumAtaturk Universitesi Arastirma Hastanesi/Ataturk Universitesi Saglik Arastirma ve Uygulama MerkeziSEVİNÇ DAKAK7SERPİL ÜÇPINAREskişehirAcibadem Eskisehir HastanesiAYFER AKTAŞ23EskişehirEskisehir Osmangazi Universitesi Saglık Arastirma ve Uygulama HastanesiKEVSER KARAOĞLU26SADİFE KARATEPESEVİYE MAHMUTOĞLU İNANGiresunGIRESUN UNIVERSITEIİ PROF. DR. A. ILHAN OZDEMİR EGITIM ARASTIRMA HASTANESIMEDİHA DÖNMEZ KURT5İstanbulKadıkoy/Kozyatagi Acibadem HastaneleriGÜLİN ÇEVİK11ÖZNUR YÜCEYASEMİN KANEKİstanbulIstanbul Saglık Bilimleri Universitesi Kanuni Sultan Suleyman Egitim ve Arastirma HastanesiGÜLDEN ANATACI6İstanbulMarmara Universitesi Istanbul Pendik Egitim ve Araştırma HastanesiSERPİL ESMEN25İstanbulBagcilar Egitim Ve Arastirma HastanesiSULTAN YURTSEVER30İstanbulIstanbul Universitesi Cerrahpaşa Tip Fakultesi HastanesiŞENAY ZUHUR25TÜLAY TOKGÖZ ŞİMŞEKİstanbulHaseki Egitim Ve Arastirma HastanesiEMINE YILMAZLAR30İstanbulIstanbul Universitesi İstanbul Tip Fakultesi HastanesiSELDA ÇELİK24SALİHA YILMAZ (Pediatric Diabetes Nurse)İstanbulIstanbul Kartal Dr. Lutfi Kirdar Egitim ve Arastirma HastanesiŞENGÜL IŞIK25İstanbulPendik Kaynarca Semt Poliklinigi Diyabet MerkeziGÜL İPEK YANILMAZ32GÖNÜL ERKUTİstanbulMedeniyet Universitesi Goztepe Egitim Ve Arastirma HastanesiDERYA KARAMAN26NURDAN YÖRÜKİstanbulIstanbul Sisli Hamidiye Etfal Egitim ve Arastirma HastanesiGÜLBAHAR POLAT25İstanbulUmraniye Egitim Ve Arastirma HastanesiZEKİYE ÇELİKÖZ28İzmirDokuz Eylul Universitesi Arastirma Uygulama HastanesiHATİCE TEKELİ ASLAN (Pediatric Diabetes Nurse)26BELGİN BEKTAŞİzmirEge Universitesi Tip Fakultesi HastanesiYILDIZ ÖZBEY31NURAN HOROZOĞLUGÜNAY DEMİR (Pediatric Diabetes Nurse)KayseriErciyes Universitesi Tip Fakultesi HastanesiSACİDE KILIÇ25NURTEN VARİYENLİ (Pediatric Diabetes Nurse)KayseriSaglik Bilimleri Universitesi Kayseri Egitim Ve Arastirma HastanesiHAYRİYE TOPRAK BEYAZ36KocaeliKocaeli Devlet HastanesiALİME KARATAŞ25KocaeliKocaeli Universitesi Arastirma ve Uygulama HastanesiYASEMİN ERKEK25YELİZ ERDEMSEVGİ AKSOY AKBEL (Pediatric Diabetes Nurse)EBRU ERCANLI (Pediatric Diabetes Nurse)KonyaKonya Egitim Ve Arastirma HastanesiFATOŞ ERDAĞI25KonyaNecmettin Erbakan Universite Hastanesi Meram Tip FakultesiFATMA ÖZDAMAR29MalatyaMalatya Egitim Arastirma HastanesiMELEK YILDIRIM7MersinMersin Toros Devlet HastanesiRABİYA DÖLEK25MersinMersin Universitesi Saglık Arastirma ve Uygulama HastanesiEYLEM TÜRK31OrduOrdu Devlet HastanesiCANDEĞER UZUNLAR30SamsunOndokuz Mayis Universitesi Tip Fakultesi HastanesiGÖNÜL GÜVELİ (Pediatric Diabetes Nurse)25GÜLAY BAYRAKSivasCumhuriyet Universitesi Arastirma ve Uygulama HastanesiZEHRA ÇELİK36SivasSivas Numune HastanesiRABİA AKÇA26TekirdağTekirdag Devlet HastanesiSERAP MAVİLİ30TrabzonKaradeniz Teknik Universitesi Saglik Uygulama Arastirma Merkezi Farabi HastanesiNİLGÜN ÇATALAHMETOĞLU25ZonguldakBulent Ecevit Universitesi Saglik Uygulama ve Arastirma HastanesiSAFİYE KÖKDEN ÇATALÇAM32

BMI

:   Body mass index

HbA1c

:   Glycated hemoglobin

HCP

:   Health care professional

ID

:   Intradermal

IM

:   Intramuscular

ITQ

:   Injection Technique Questionnaire

IU

:   International unit (of insulin)

LH

:   Lipohypertrophy

LH+

:   Patients with lipohypertrophy

LH−

:   Patients without lipohypertrophy

PD

:   Pharmacodynamics

PK

:   Pharmacokinetics

T1DM

:   Type 1 diabetes

T2DM

:   Type 2 diabetes

TDD

:   Total daily dose (of insulin)

ITQ Turkey Study Group (see Appendix Table [15](#Tab15){ref-type="table"}).
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To view enhanced digital features for this article go to 10.6084/m9.figshare.6552659.
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